for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avrobio Inc

AVRO.OQ

Latest Trade

9.83USD

Change

-0.24(-2.38%)

Volume

91,162

Today's Range

9.59

 - 

10.03

52 Week Range

7.45

 - 

22.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.07
Open
9.99
Volume
91,162
3M AVG Volume
9.94
Today's High
10.03
Today's Low
9.59
52 Week High
22.50
52 Week Low
7.45
Shares Out (MIL)
41.77
Market Cap (MIL)
420.58
Forward P/E
-3.66
Dividend (Yield %)
--

Next Event

AVROBIO Inc at JMP Securities Life Sciences Virtual Conference

Latest Developments

More

AVROBIO Reports Q1 Loss Per Share Of $0.65

Avrobio Provides Regulatory Update On Investigational Avr-Rd-01 For Fabry Disease

AVROBIO Reports Q4 Net Loss Per Share $0.73

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Avrobio Inc

AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.

Industry

Biotechnology & Drugs

Contact Info

1 Kendall Sq Bldg 300 Ste 201

CAMBRIDGE, MA

02139-1562

United States

+1.781.9626030

http://www.avrobio.com

Executive Leadership

Bruce Booth

Independent Chairman of the Board

Geoff Mackay

President, Chief Executive Officer, Director

Erik Ostrowski

Chief Financial Officer, Treasurer

Christopher Mason

Chief Scientific Officer

Diana M. Escolar

Chief Medical Officer

Key Stats

2.00 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-3.620

2019

-2.660

2020

-3.310

2021(E)

-2.754
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.81
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-49.23
Return on Equity (TTM)
-46.79

Latest News

Latest News

BRIEF-Avrobio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* AVROBIO ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

BRIEF-Avrobio Announces New Patients Dosed In Gaucher Disease And Cystinosis Clinical Trials

* AVROBIO ANNOUNCES NEW PATIENTS DOSED IN GAUCHER DISEASE AND CYSTINOSIS CLINICAL TRIALS

BRIEF-Avrobio Announces The Appointment Of Kim Raineri As Chief Manufacturing And Technology Officer

* AVROBIO ANNOUNCES THE APPOINTMENT OF KIM RAINERI AS CHIEF MANUFACTURING AND TECHNOLOGY OFFICER Source text for Eikon: Further company coverage:

BRIEF-Avrobio Reports Updated Clinical Data From Investigational Gene Therapy Programs For Fabry Disease And Cystinosis

* AVROBIO REPORTS UPDATED CLINICAL DATA FROM INVESTIGATIONAL GENE THERAPY PROGRAMS FOR FABRY DISEASE AND CYSTINOSIS

BRIEF-Avrobio Reports 1Q 2020 Financial Results And Provides Business Update

* AVROBIO REPORTS 1Q 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Avrobio To Collaborate With Saladax Biomedical On New High-Speed Diagnostic Assay

* AVROBIO TO COLLABORATE WITH SALADAX BIOMEDICAL ON NEW HIGH-SPEED DIAGNOSTIC ASSAY USED WITH BUSULFAN CONDITIONING TO ENABLE WIDESPREAD COMMERCIALIZATION OF AVROBIO’S PROPRIETARY PLATFORM GLOBALLY Source text for Eikon: Further company coverage:

BRIEF-Avrobio Says Essential Laboratory And Manufacturing Activities Currently Uninterrupted

* AVROBIO OUTLINES RESPONSE TO COVID-19 AND CURRENT ASSESSMENT OF BUSINESS IMPACT

BRIEF-Avrobio Reports Fourth Quarter Results

* AVROBIO REPORTS FOURTH QUARTER AND FISCAL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Avrobio Receives Orphan Drug Designation From U.S. FDA For AVR‑RD‑04 For Cystinosis

* AVROBIO RECEIVES ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR AVR-RD-04 FOR CYSTINOSIS Source text for Eikon: Further company coverage:

BRIEF-Avrobio Announces Pricing Of Underwritten Public Offering Of $100 Million Of Common Stock

* AVROBIO ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF COMMON STOCK

BRIEF-Avrobio Presents Positive Initial Data For Its Investigational Cystinosis Program And Plato Tm Platform, As Well As Positive Data Out To 32 Months For Its Ongoing Investigational Fabry Program

* AVROBIO PRESENTS POSITIVE INITIAL DATA FOR ITS INVESTIGATIONAL CYSTINOSIS PROGRAM AND PLATO TM PLATFORM, AS WELL AS POSITIVE DATA OUT TO 32 MONTHS FOR ITS ONGOING INVESTIGATIONAL FABRY PROGRAM

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up